As we step into 2025, we are happy to announce that our study results were published in Cytotherapy journal. Co-authored with researchers from the University of Chicago Medical Center and CellReady, the publication highlights MARS® Bar — a new, column-free instrument dedicated to the enrichment of CD4+ and CD8+ T-lymphocytes for clinical cell manufacturing. The work emphasizes the transformative potential of MARS platform in advancing cell therapy field.
Why does this innovation matter for cell therapy development?
· Innovative, cost-effective technology: MARS Bar enables fast and efficient CD4+/CD8+ T-cell isolation, operating within a closed, cleanroom-compatible system. The unique column-free design mitigates common challenges, including cell clogging, and significantly reduces processing time.
· Superior performance: the platform achieves T-cell purity over 95%, with recoveries of up to 73%. It supports both fresh and cryopreserved starting materials, making it a versatile tool suitable for various clinical manufacturing settings.
· Fast, simple workflow: by integrating LOVO and MARS, we simplified the cell separation workflow, eliminating manual centrifugation and reducing process times. By eluting selected T cells directly into cell culture medium, we enable a seamless connection to the G-Rex bioreactor, eliminating the need for the media exchange step in the process. These advancements significantly lower production costs and enhance scalability for the development of new CAR-T and other cell therapies.
· Future impact: MARS Bar is an innovative tool designed for next-generation T-cell therapy development, aligning with the growing demand for “point-of-care” manufacturing.
A look ahead: keeping the momentum in 2025
The study is a result of combined research and development efforts of leaders in cell therapy innovation. This achievement sets the tone for a dynamic year ahead! We will continue our commitment to innovation, aiming to deliver cutting-edge solutions that empower researchers and clinicians to develop affordable, accessible therapies for all patients. Together with our partners, we continue to push the boundaries of what’s possible in clinical cell manufacturing. Here’s to a remarkable 2025 — full of progress, innovation, and meaningful contributions to global healthcare.
Read the publication here: Langa P, Sharma K, Sellers DL, Placencia V, Smith EA, Fick D, et al. Enrichment of CD4+ and CD8+ T-Lymphocytes with a Column-Free Flow Based Device for Clinical Cell Manufacturing. Cytotherapy. 2025. Available from: https://doi.org/10.1016/j.jcyt.2024.12.009
